We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01920191
Recruitment Status : Completed
First Posted : August 9, 2013
Last Update Posted : April 20, 2016
Immatics Biotechnologies GmbH
Oncovir, Inc.
Information provided by (Responsible Party):
Pierre-Yves Dietrich, University Hospital, Geneva

Brief Summary:
RATIONALE : IMA 950 is multi tumour-associated peptides (TUMAPs) vaccine, these peptides have been identified on primary glioblastoma multiforme (GBM) cells. Poly-ICLC is a potent vaccine adjuvant with broad innate and adaptive immune enhancing effects. IMA 950 and Poly-ICLC will be administered to patients alongside standard primary therapy for glioblastoma. This includes the alkylating drug temozolomide (TMZ). Effective vaccine-induced immune responses associated with prolonged survival have been observed in glioblastoma patients during TMZ adjuvant therapy, suggesting a possible synergistic effect. A second component of glioblastoma standard treatment is external beam irradiation of the tumor site post-surgery. As a side effect, potentially beneficial tumor-infiltrating immune cells may also be killed by radiation. However, the combination of radiation with immunotherapy has been suggested to be favorable both in pre-clinical models.

Condition or disease Intervention/treatment Phase
CNS Tumor, Adult Biological: IMA 950 Biological: Poly ICLC Other: Immunomonitoring Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients
Study Start Date : August 2013
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaccines

Arm Intervention/treatment
Experimental: IMA 950 and Poly ICLC Biological: IMA 950
Biological: Poly ICLC
Other Name: Hiltonol

Other: Immunomonitoring
Blood samples, DTH analysis

Primary Outcome Measures :
  1. Tolerability and safety of IMA950 adjuvanted with Poly-ICLC when given together with temozolomide, using CTCAE V 4.0 [ Time Frame: up to 2 years ]

Secondary Outcome Measures :
  1. 6, 9 month progression free survival (PFS) using gadolinium enhanced MRI and clinical assessment according to revised RANO criteria [ Time Frame: up to 2 years ]
  2. Overall survival (OS) [ Time Frame: up to 2 years ]
  3. Immunologic endpoints [ Time Frame: up to 2 years ]

    Correlation between clinical and immunological response. Blood sampling at baseline (week 4 and 5 after beginning of radiotherapy with concomitant temozolomide) and at week 10,11,12,16,19,23,27 and 31.

    Punch biopsy at DTH (Delayed Type Hypersensitivity) site performed 48h after DTH skin test 7 days after Vaccination 7.

    • evaluation of peptide immunogenicity by tetramer staining
    • analysis of memory, activation and homing marker expression by tetramer positive cells
    • analysis of cytokine secretion and proliferation by antigen-specific CD4 and CD8 T cells
    • analysis of the presence of T regulatory and myeloid-derived suppressor cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological documentation of glioblastoma. For experimental purposes only, 5 additional grade III astrocytoma may be included (these cases will not be included in the endpoints analysis).
  2. Patients must have completed radiation therapy with concomitant temozolomide.
  3. HLA-A2 positive.
  4. Eastern Cooperative Oncology Group performance status of 0 or 1 (Appendix1).
  5. Age > 18 years, life expectancy of least 4 months.
  6. Patient must be on stable or decreasing dose of steroids, with a maximal dose of Dexamethasone of 4mg/day.
  7. Adequate bone marrow, liver and kidney function.
  8. Hepatitis B serology negative (HBcAg-seronegative)
  9. Written (signed and dated) informed consent. Capable of co-operating with standard therapy and IMA950 with Poly-ICLC vaccinations and follow-up.

Exclusion Criteria:

  1. Any other vaccination given within 2 weeks before first IMA950 vaccination.
  2. History of cardiac disease: congestive heart failure > New York heart association class 2, active CAD, cardiac requiring anti-arrhythmic therapy or uncontrolled hypertension.
  3. History of HIV infection or chronic hepatitis B or C or clinical active infections.
  4. Patients with evidence of history bleeding diathesis.
  5. Pregnant or potentially pregnant patients. Women of childbearing age must be tested for pregnancy (serum or urine HCG) before treatment and must not contemplate pregnancy during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01920191

Layout table for location information
Geneva University Hospitals, Centre of Oncology
Geneva, Switzerland, CH-1211
Sponsors and Collaborators
University Hospital, Geneva
Immatics Biotechnologies GmbH
Oncovir, Inc.
Layout table for investigator information
Principal Investigator: Pierre-Yves Dietrich, Professor University Hospital, Geneva
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pierre-Yves Dietrich, Professor, University Hospital, Geneva
ClinicalTrials.gov Identifier: NCT01920191    
Other Study ID Numbers: IMA950 Poly ICLC
First Posted: August 9, 2013    Key Record Dates
Last Update Posted: April 20, 2016
Last Verified: April 2016
Keywords provided by Pierre-Yves Dietrich, University Hospital, Geneva:
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Interferon Inducers
Immunologic Factors
Physiological Effects of Drugs